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The endothelium, the inner layer of vessels, represents a huge organ, an important regulator and mediator 
of vasoactive factors. A number of common diseases including preeclampsia, hypertension, coronary heart 
disease and diabetes have been linked to poor endothelial function. Tests have been developed to measure 
endothelial function, but have not been suitable for population-based studies until they became non-
invasive. Ultrasound imaging of the vessel diameter and the blood velocity has opened that door. The 
techniques are used to assess vascular distension and increased flow velocity as a response to reactive 
hyperemia after arterial occusion or administration of different drugs. Here we discuss the background, 






Endothelium is a single layer of cells lining the inner 
wall of blood vessels. This endothelial lining provides 
an interface with the blood stream and plays an im-
portant role in sensing and responding to stimuli 
activating various vasoactive systems that function as 
mediators. These endothelium-derived substances in-
clude vasodilators (e.g. nitric oxide (NO) and prosta-
glandins) and vasoconstrictors (e.g. endothelin-1). 
Substances derived from the endothelium stabilize 
platelets, control the migration of white blood cells 
and lipoproteins into the intima, and discourage the 
influx of inflammatory cells. Furthermore, they control 
the dimension of the blood vessels by their action on 
the vascular smooth muscle cells of the media. An 
impaired balance between vasoconstrictors and vaso-
dilators, increased vascular permeability and enhanced 
expression of cell adhesion molecules, which support a 
procoagulatory proinflammatory state, characterizes 
endothelial dysfunction. Endothelial dysfunction has 
been associated with the pathogenesis of a variety of 
disorders, such as ischemic heart disease (1,2), 
essential hypertension (3), dyslipidemia (4), diabetes 
mellitus (5,6) and preeclamptic toxemia of pregnancy 
(7,8) that have a significant impact on the community 
health. Understanding the role of endothelium in the 
pathogenesis has led to better strategies in the manage-
ment of conditions such as ischemic coronary heart 
disease, pulmonary hypertension, erectile dysfunction 
etc. in recent years. A number of epidemiological 
studies have shown a link between endothelial 
dysfunction with later development of cardiovascular 
events (9-12). 
 Certain diseases that are pregnancy specific, such as 
gestational diabetes and preeclampsia, not only ad-
versely affect the fetal and maternal wellbeing during 
pregnancy but also have a long-term effect on the 
health of the woman and her offspring. For some con-
ditions, such as gestational trophoblastic disease and 
gestational diabetes, there exists a well-defined follow 
up policy to subsequently identify and manage their 
consequences even though the incidence of adverse 
events may be relatively low. For example, following a 
diagnosis of gestational trophoblastic disease (even 
after benign hydatidiform mole) checking urinary or 
serum beta-hCG at about 6 weeks after any subsequent 
pregnancy event is a routine in most developed coun-
tries. Women who had gestational diabetes are usually 
offered a glucose tolerance test (or at least a fasting 
blood glucose measurement) 3 months postpartum and 
yearly thereafter. The women who had preeclampsia 
are at increased risk of cardiovascular events, such as 
hypertension, ischemic heart disease and stroke, later 
in life (13-16). However, no general policy exists to 
counsel, prevent, diagnose or screen for adverse health 
consequences following preeclampsia and provide 
early intervention. One of the difficulties is, not 
knowing who among these women are likely to suffer 
the adverse effects and who may benefit from inter-
ventions. There is some indication that these women 
have had an underlying endothelial dysfunction, but 
more observational as well as larger epidemiological 
studies are required to verify these assumptions. Even 
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the physiological changes in maternal endothelial 
function during pregnancy are not well defined yet. 
One of the major problems has been that the invasive 
methods of studying endothelial function are not app-
ropriate in this regard and noninvasive methods have 
not been validated well until recently. 
 
 
METHODS FOR ASSESSING ENDOTHELIAL 
FUNCTION 
 
A variety of methods can be used in vitro and in vivo 
to assess endothelial function. In the experimental 
settings, investigators have used nitroglycerin to assess 
the effect of maximum vascular smooth muscle re-
laxation, NG-monomethyl-L-arginine (L-NMMA) to 
inhibit NO production by endothelium, L-arginine to 
stimulate NO production, antioxidants to slow down 
and oxidants to hasten the breakdown of NO, phospho-
diesterase 5 (PDE5) inhibitors to potentiate and pro-
long the effect of NO, and acetylcholine or reactive 
hyperemia to stimulate NO production by endotheli-
um. However, vascular reactivity tests are mostly used 
to assess endothelial function in the clinical settings. 
Today two invasive (brachial artery catheterization 
with venous occlusive strain-gauge plethysmography 
and intracoronary agonist infusion with Doppler flow 
wire to measure changes in coronary artery blood 
flow) and two non-invasive methods (ultrasonographic 
assessment of changes in brachial artery diameter ± 
blood flow in response to postocclusive reactive hy-
peremia and non-invasive assessment of coronary flow 
reserve using Doppler echocardiography) represent the 
commonly employed methods in clinical practice. In-
erestingly, there appears to be a close relationship 
between endothelial function in the coronary and peri-
pheral circulations (17). However, whether endothelial 
dysfunction in one vascular bed correlates with endo-
thelial function in other vascular beds and reflects 
global endothelial function remains controversial. 
 Invasive methods are obviously not appropriate for 
studying asymptomatic subjects and are therefore not 
suitable for population-based epidemiological studies. 
Two other methods have been proposed for the evalua-
tion of endothelial function: laser Doppler iontophore-
sis to assess response of forearm skin microvessels to 
acetylcholine (18-21) and pulse-wave analysis using 
vascular tonometry (22-24). Although these methods 
show correlation with flow-mediated dilatation (FMD) 
they are still not generally accepted methods of measu-
ring endothelial function. Their results may be affected 
by several factors, such as skin conductivity, current 
induced vasodilatation, hemodynamic status, vascular 
structure and vessel wall properties etc. Therefore, 
FMD of brachial artery is perhaps the most appropriate 
method for large-scale epidemiological studies and for 
serial evaluation of endothelial function, whereas 
investigation of coronary flow reserve using Doppler 
echocardiography may be contemplated in high-risk 
population such as in women with a previous history 




FLOW-MEDIATED VASODILATATION (FMD) 
 
A sudden increase in the endothelial shear stress acting 
on the arterial endothelium induces vasodilatation of 
the peripheral conduit arteries in vivo, which is mainly 
mediated by an increased endothelial NO release (25). 
This capacity of endothelium to generate bioactive NO 
in conduit arteries can be evaluated by measuring the 
flow-mediated dilatation of the brachial artery (percen-
tage increase in diameter and/or volume blood flow 
above the baseline values) evoked by post-occlusive 
reactive hyperemia. High-resolution ultrasonography 
with a 10 MHz linear array transducer is commonly 
employed for this purpose and authoritative guidelines 
(26), technical details (27,28) and extensive reviews 
(29-31) have been published on this subject. 
 In brief, the examination is preferably performed in 
the morning in a fasting state as food intake can alter 
the arterial response (32). Smoking, tea, coffee or any 
other stimulants should be avoided before examina-
tion. It is advisable to perform the examination in a 
temperature controlled (23±1 degree centigrade) room 
with the subjects lying in supine position (pregnant 
women should be examined in a semi recumbent or 
left lateral position to avoid hypotension due to the 
pressure of the gravid uterus on the vena cava inferior). 
In premenopausal women, it is important to investigate 
the FMD consistently during a particular phase in the 
menstrual cycle (33). After a 10 min rest, blood pres-
sure is measured in the left arm using an automatic 
equipment. An electrocardiogram is continuously 
recorded and displayed on the screen of the ultrasound 
machine. A conventional mercury sphygnomanometer 
cuff is loosely fitted around the upper arm (some in-
vestigators prefer to fit it around the forearm, but the 
proximal limb occlusion causes larger increase in 
brachial artery diameter leading to more reproducible 
measurements). Brachial artery of the right arm is lo-
cated approximately 5 cm proximal to the antecubital 
fossa using a high-resolution linear ultrasound probe 
(7.5-12MHz). Colour Doppler is used to help the iden-
tification of the artery. A longitudinal image of the 
artery is obtained keeping the ultrasound beam close to 
90 degrees to the vessel walls and the inner diameter is 
measured in a frozen two-dimensional B-mode image 
(figure 1a). Blood flow velocity waveforms (figure 1c) 
are obtained from the brachial artery using pulsed-
wave Doppler keeping the angle of insonation <60 de-
grees. After the baseline measurements are performed 
the brachial artery is occluded by quickly inflating the 
upper arm cuff to a pressure 50 mmHg above the 
systolic blood pressure. After 5 minutes the cuff is 
released (at least 4.5 minutes of occlusion is required 
to obtain maximum response) (27). The blood flow 
velocity waveforms are recorded within 15 seconds of 
cuff deflation (figure 1d) and the diameter after 60 se-
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Figure 1.  Inner diameter (a) and blood flow velocity waveform (c) of the brachial artery in a healthy woman at baseline, and during 





Figure 2.  Left descending coronary artery blood flow velocity waveform at baseline (A), 30 seconds (B), 1 minute (C) and 2 minutes (D) 
after the start of intravenous adenosine infusion in a healthy woman. The mean (time-averaged maximum) diastolic coronary flow 
velocity increased from 20.6 cm/s at baseline to 75.4 cm/s at 1 minute indicating normal coronary flow reserve. 
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conds (figure 1b) as the peak diameter increase occurs 
between 60 to 70 seconds after the cuff release (34). 
The diameter is measured consistently at the same pe-
riod of cardiac cycle, which is identified with the help 
of EKG and the cine-loop facility of the ultrasound 
machine. An average of at least 3 measurements 
should be used. 
 The FMD is calculated as the percentage change in 
vessel diameter compared with baseline, i.e. FMD % = 
100*(diameter after cuff deflation – baseline diame-
ter)/ baseline blood flow. Blood flow is calculated as: 
Time-averaged maximum velocity * π (brachial artery 
diameter/2)2. Increase in blood flow % = 100*(blood 
flow after cuff deflation – baseline blood flow)/base-
line blood flow. Other parameters such as pulsatility 
index and resistance index can also be calculated from 
the flow velocity waveforms. 
 Peak FMD is approximately 8.5 (7-10)% of base-
line diameter and may be even higher during preg-
nancy depending on the gestational age. A FMD of ≤ 
4.5% from the baseline has been suggested as the cut-
off value for identifying endothelial dysfunction (11) 
but such a level has not been established for the preg-
nant population. 
 
CORONARY FLOW RESERVE (CFR)  
Coronary flow reserve is the ratio of maximum (stimu-
lated) to baseline (resting) coronary blood flow that 
has been used as a measure of coronary endothelial 
function. Invasive studies have shown a link between 
impaired coronary microvascular dilatation (endothe-
lial dysfunction) and adverse cardiovascular events 
(35,36). Until recently, methods of assessing CFR had 
been invasive (coronary sinus thermodilution, coro-
nary sinus sampling of diffusible tracers, intracoronary 
Doppler guidewire), semi-invasive (transesophageal 
echocardiography) or expensive and cumbersome (nu-
clear magnetic resonance, positron emission tomogra-
phy, single positron emission computed tomography, 
myocardial scintigraphy). Because of the easier acces-
sibility, brachial artery FMD has been used to reflect 
the reactivity of other vascular beds including coro-
nary, although there are clear differences among them 
in regards to vascular architecture, vascular resistance 
blood flow pattern, and metabolism. With advances in 
ultrasound technology it became possible to visualize 
and measure coronary artery blood flow using trans-
thoracic Doppler echocardiography (37-42) that allo-
wed direct investigation of the coronary vasculature 
noninvasively. Although coronary blood flow at base-
line and during maximal arteriolar dilatation following 
agonist (e.g. adenosine or dipyridamole) infusion is 
difficult to quantify accurately using echo Doppler, the 
ratio between hyperemic and baseline coronary blood 
flow velocity provides a good measure of endothelial 
function. CFR evaluated by transthoracic Doppler 
echocardiography corresponds to invasively measured 
CFR using intracoronary Doppler guidewire technique 
(43,44). 
 The CFR is measured usually in the left descending 
coronary artery (LAD) using conventional echo Dopp-
ler equipment with a 3.5 to 6 MHz phased-array ultra-
sound transducer. The LAD is visualized using colour 
Doppler (pulse repetition frequency adjusted at a rela-
tively low velocity range of 12-24 cm/s and sample 
volume 3-5 mm) as a circular vessel in the interven-
tricular groove with predominant diastolic flow signal. 
The transducer is then rotated 80-90 degrees to obtain 
longitudinal view of the LAD. The coronary blood 
velocity waveforms (figure 2) are obtained using 
pulsed-wave Doppler keeping the angle of insonation 
as low as possible. Following baseline measurements, 
intravenous infusion of adenosine in the cubital vein 
(140µg/kg/min) is started and coronary blood flow 
velocity is recorded at 30 seconds, 1 minute and 2 
minutes after the start of infusion. Adenosine acts 
instantaneously achieving maximum coronary vaso-
dilatation in 40-60s. The CFR is calculated as the ratio 
of hyperaemic to resting (baseline) mean (time-
averaged maximum) diastolic coronary flow velocity. 
A CFR value of ≤ 2 is generally considered as a cut-
off value to identify significant coronary artery 
endothelial dysfunction. However, the method requires 
considerable expertise and patience. 
  
ENDOTHELIAL FUNCTION IN NORMAL 
PREGNANCY 
 
Few observational studies have indicated that FMD is 
enhanced in normal pregnancy (45-48) and the NO-
dependent vasodilatation appears to improve with 
advancing gestational age regardless of concurrently 
appearing lipid changes (49) although some studies 




PREECLAMPSIA AND MATERNAL HEALTH 
 
Endothelial dysfunction is commonly observed in 
preeclampsia (8,51). Even though the link between 
shallow trophoblast invasion, inadequate spiral artery 
remodeling, abnormal placentation and generalized 
maternal endothelial dysfunction remains unclear, 
impaired endothelial function is considered to be an 
important factor in the pathogenesis of preeclampsia. 
Impaired vasodilatory response to endothelium-
dependent agonists like acetylcholine and bradykinin 
in isolated myometrial (52,53), omental (54) and cu-
taneous (55) resistance arteries have provided direct 
evidence of vascular endothelial dysfunction in pre-
eclampsia. Investigators have also used other indirect 
markers (e.g. fibronectin, Von Willebrand factor, en-
dothelin 1, asymmetric dimethyl arginine etc.) to show 
that endothelial function is impaired in peeclampsia 
(56). Reduced FMD in second trimester has also been 
reported to be associated with increased risk of pre-
eclampsia (57). However, endothelial dysfunction may 
not be generalized and may be confined to or be more 
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pronounced in the utero-placental vasculature, as it is 
shown that endothelin 1 concentrations are higher in 
the uterine vein compared to the brachial vein in wo-
men with preeclampsia (58). Nevertheless, failure of 
shear stress-mediated dilation in myometrial arteries 
might contribute to impaired uteroplacental blood flow 
in preeclampsia (59), and abnormal uterine artery 
Doppler waveform (Figure 3) in the second trimester, 
which is an indicator of increased utero-placental 
resistance and a risk factor for the development of pre-
eclampsia, is commonly associated with reduced FMD 
in normotensive pregnant women (60). 
 Women with cardiovascular risk factors are pre-
disposed to preeclampsia (61) and vice versa (13-16). 
Therefore, endothelial dysfunction may be a cause or a 
consequence of preeclampsia. It is not clear whether 
endothelial function is already impaired even before 
pregnancy in women who later develop preeclampsia, 
and whether it further deteriorates during pregnancy. 
Similarly, it is not known whether women who had 
preeclampsia continue to have endothelial dysfunction 
following delivery, how long the dysfunction lasts, and 
whether it continues to deteriorate. Impaired FMD has 
been shown to be present 1-3 years after preeclamptic 
pregnancy (62,63) and microvascular dysfunction after 
15-25 years (64). Are these women who continue to 
have endothelial dysfunction more at risk of develo-
ping cardiovascular events than those who do not? 
Longitudinal studies are urgently needed to answer 
these questions. Assessment of endothelial function 
may help in risk stratification during pregnancy as well 





Ultrasonographic assessment of maternal endothelial 
function can be used as an epidemiological tool. It may 
help in predicting the development and severity of 
preeclampsia, especially in combination with other 
tests. Additionally, it may identify a subgroup of 
women who are at increased risk of developing cardio-
vascular disease later in life following adverse preg-
nancy events, such as preeclampsia and intrauterine 
fetal growth restriction. These women may benefit 
from counselling, appropriate follow up, advice on 
lifestyle modification, diet, and in some cases primary 
pharmacological prophylaxis. Incorporation of mater-
nal endothelial function testing using appropriate met-
hods into ongoing population-based epidemiological 
studies in Norway could be a step in the right direction 









Figure 3.  Normal uterine artery blood flow velocity waveforms at 23 weeks of gestation is characterized by 
low pulsatile velocity (a). An augmented pulsatile waveform signifies increased utero-placental vascular 
impedance (b). Arrow points to the protodiastolic notch, another sign of increased impedance. 
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